As WHO member states gathered in Geneva for the 2018 World Health Assembly, Geneva Network co-ordinated a summit for pro-innovation think tanks and thought leaders from around the world. Thanks are due to the World Intellectual Property Organisation which kindly offered meeting facilities and lunch in its headquarters building. WIPO Director General Francis Gurry started the day […]
This author has yet to write their bio.Meanwhile lets just say that we are proud gnadm contributed a whooping 31 entries.
Entries by gnadm
Following growing concern about the sustainability of healthcare systems, in the summer of 2016 EU Health Ministers invited the European Commission (EC) to undertake a review of the Intellectual Property (IP) incentives that underpin biomedical innovation. This document is a joint statement by a coalition of like-minded think tanks, civil society groups and academics who […]
For South Africa to join the ranks of high-income countries in the longer term it needs to start building a knowledge economy. That means ensuring its frameworks for the protection of intellectual property are of the highest standard, to attract international investment and know-how, and provide certainty to local innovators. South Africa’s journey to a […]
The debate around innovation and health has been monopolised over the last decade by civil society groups that claim the current system of drug development, underpinned by markets and intellectual property rights, does not function and must be replaced by alternative systems that envisage a far greater role for government. In reality, there is no […]
Alors que les populations sud africaines ont un besoin cruel de médicaments, les nouveaux médicaments ont un mal fou à pénétrer le marché du pays. Pourquoi ? Dans leur article, Urbach et Stevens, dénoncent la lourdeur de la réglementation sud africaine qui entrave lourdement la mise sur le marché de nouveaux médicaments. Les démarchent peuvent […]
The UN High Level Report on Access to medicines threatens the nascent boom in biopharmaceutical R&D in middle-income such as India and China, according to Geneva Network, a UK-based research organisation working on international trade, health and intellectual property issues. Since China and India upgraded their protection for intellectual property in the mid 2000s, their […]
Our research on the impact of increased periods of data exclusivity in Japan and Canada on pharmaceutical spending is mentioned in this Washington Post article.
Countries need to commit to abolishing import tariffs on drugs Geneva, September 29, 2015 ─ A new study from Geneva Network has found that the global volume of trade in medicines that have their price increased by tariffs is growing at 21% per year. This means more patients in countries such as India, Brazil, Pakistan […]
What’s happened in the first six months of Geneva Network – new studies on IP, health and trade. Find out more